Press Releases

Press Releases

Filters
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer
Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders
Viatris to Participate in the Jefferies London Healthcare Conference
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance
Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row
Rajiv Malik to Retire as President of Viatris Effective April 1, 2024
Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking
Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
Displaying 11 - 20 of 96